KR20240105519A - Cns 부종과 관련한 손상 또는 병태의 치료 방법 - Google Patents

Cns 부종과 관련한 손상 또는 병태의 치료 방법 Download PDF

Info

Publication number
KR20240105519A
KR20240105519A KR1020247021781A KR20247021781A KR20240105519A KR 20240105519 A KR20240105519 A KR 20240105519A KR 1020247021781 A KR1020247021781 A KR 1020247021781A KR 20247021781 A KR20247021781 A KR 20247021781A KR 20240105519 A KR20240105519 A KR 20240105519A
Authority
KR
South Korea
Prior art keywords
subject
hours
glyburide
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247021781A
Other languages
English (en)
Korean (ko)
Inventor
스벤 마틴 제이콥슨
Original Assignee
레메디 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레메디 파마슈티칼즈, 인크. filed Critical 레메디 파마슈티칼즈, 인크.
Publication of KR20240105519A publication Critical patent/KR20240105519A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247021781A 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법 Ceased KR20240105519A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema
KR1020187012950A KR102681027B1 (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012950A Division KR102681027B1 (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Publications (1)

Publication Number Publication Date
KR20240105519A true KR20240105519A (ko) 2024-07-05

Family

ID=58488580

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247021781A Ceased KR20240105519A (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법
KR1020187012950A Active KR102681027B1 (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187012950A Active KR102681027B1 (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Country Status (15)

Country Link
US (4) US20180280325A1 (enExample)
EP (1) EP3359162B1 (enExample)
JP (4) JP7349786B2 (enExample)
KR (2) KR20240105519A (enExample)
CN (2) CN108348534A (enExample)
AU (3) AU2016335767B2 (enExample)
BR (1) BR112018006925A2 (enExample)
CA (1) CA3001321A1 (enExample)
EA (1) EA201890893A1 (enExample)
ES (1) ES2940669T3 (enExample)
HK (1) HK1257542A1 (enExample)
IL (1) IL258509B2 (enExample)
MA (1) MA45574A (enExample)
MX (1) MX392466B (enExample)
WO (1) WO2017062765A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027983B1 (pt) 2012-05-08 2022-05-24 Aeromics, Inc Uso de inibidores de aquaporina seletivos
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
CN113874002A (zh) * 2019-05-02 2021-12-31 生物切萨皮克有限责任公司 治疗患有中枢神经系统挫伤的受试者的方法
TW202214561A (zh) * 2020-07-17 2022-04-16 大陸商上海森輝醫藥有限公司 磺醯脲類衍生物及其醫藥用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203853A1 (en) 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DK2438913T3 (da) * 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
WO2009073711A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203853A1 (en) 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sheth et al., Neurocrit Care (2014) 21:43-51

Also Published As

Publication number Publication date
AU2016335767A8 (en) 2018-06-28
IL258509B (en) 2022-12-01
IL258509B2 (en) 2023-04-01
JP2023053274A (ja) 2023-04-12
KR20180063296A (ko) 2018-06-11
JP2021073317A (ja) 2021-05-13
WO2017062765A1 (en) 2017-04-13
BR112018006925A2 (pt) 2018-10-16
US20250017880A1 (en) 2025-01-16
CA3001321A1 (en) 2017-04-13
AU2016335767B2 (en) 2022-10-06
EP3359162A1 (en) 2018-08-15
MX392466B (es) 2025-03-24
EP3359162A4 (en) 2019-08-28
IL258509A (en) 2018-05-31
JP2024164167A (ja) 2024-11-26
US20240216309A1 (en) 2024-07-04
CN108348534A (zh) 2018-07-31
US11951085B2 (en) 2024-04-09
JP7349786B2 (ja) 2023-09-25
EP3359162B1 (en) 2022-12-21
AU2022279369B2 (en) 2025-02-13
AU2022279369A1 (en) 2023-01-19
JP7592768B2 (ja) 2024-12-02
KR102681027B1 (ko) 2024-07-02
ES2940669T3 (es) 2023-05-10
HK1257542A1 (zh) 2019-10-25
JP2018530564A (ja) 2018-10-18
US20180280325A1 (en) 2018-10-04
AU2025202620A1 (en) 2025-05-01
AU2016335767A1 (en) 2018-05-24
MX2018004286A (es) 2018-08-09
US20220125750A1 (en) 2022-04-28
EA201890893A1 (ru) 2018-09-28
CN115737816A (zh) 2023-03-07
MA45574A (fr) 2019-05-15

Similar Documents

Publication Publication Date Title
KR102681027B1 (ko) Cns 부종과 관련한 손상 또는 병태의 치료 방법
Liotta Management of cerebral edema, brain compression, and intracranial pressure
Cenkowski et al. Hemodynamic effects of low-dose bupivacaine spinal anesthesia for cesarean section: A randomized controlled trial
JP2018530564A5 (enExample)
US12251389B1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Narotam et al. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation
US20250345346A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Ibrahim et al. A Comparative Study of Infusion of Ephedrine and Phenylephrine on Hemodynamic Stability After Spinal Anesthesia in Elderly Patients Undergoing Lower Limb Orthopedic Surgeries
Kla Best Practice & Research Clinical Anaesthesiology
May et al. Treatment of elevated intracranial pressure
US20250325564A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US20250325504A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
JP2022531312A (ja) 中枢神経系挫傷に苦しむ対象の治療方法
AbdelRady et al. Role of Granisetron in preventing hypotension after spinal anaesthesia with Levobupivacaine in rheumatic patients undergoing elective cesarean section: A randomized controlled trial
WO2025193971A1 (en) Methods of treating and reducing the likelihood of developing epilepsy
WO2025212154A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212155A1 (en) Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000